Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00308191 · ClinicalTrials.gov registry record · Phase 3
A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD
A Phase 3 study, sponsored by Dey.
- Completed
- Registry status
- Phase 3
- Development phase
- 128
- Enrollment target
NCT00308191 is a Phase 3 study that has completed, run by Dey. The registered enrollment target is 128 participants.
The verdict
NCT00308191, a Phase 3 study, has completed, sponsored by Dey.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 128 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of the concomitant treatment of formoterol fumarate with tiotropium bromide compared to treatment with tiotropium bromide alone.
Interventions
- DRUG Formoterol Fumarate
- DRUG Tiotropium Bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2006-04 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00308191
The ClinicalTrials.gov registry entry for NCT00308191 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dey, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Formoterol Fumarate is the first listed.
NCT00308191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00308191 about?
NCT00308191 is a clinical study titled "A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD". The purpose of this study is to evaluate the safety and efficacy of the concomitant treatment of formoterol fumarate with tiotropium bromide compared to treatment with tiotropium bromide alone.
What is the current status of trial NCT00308191?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 128 participants. The study started on 2006-04. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00308191?
The interventions under investigation include: Formoterol Fumarate (DRUG), Tiotropium Bromide (DRUG).
Who is sponsoring clinical trial NCT00308191?
This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.